FEELM
21.11.2022 12:55:43 CET | Business Wire | Press release
FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, was pleased to have its European Division Director, Echo Liu, deliver a keynote speech at the UKVIA Vaping Industry Forum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005424/en/
Echo presenting a speech at the UKVIA. (Photo: Business Wire)
In her address to 300 delegates at the UK’s largest dedicated business-to-business vaping conference, Echo Liu reiterated FEELM’s belief that innovation is key to the future success of the industry: finding solutions to the major challenges of customer satisfaction, harm reduction, and Climate Change. The highlights of her speech included:
“By every metric – flavour, taste, noise, or even harm reduction – our patented FEELM ceramic coil has revolutionised the performance of our clients’ products. FEELM Max, the world’s first ceramic coil disposable pod solution, introduces a number of breakthrough innovations, including 25% more puffs with the same e-liquid volume versus other coil technologies. It also resolves issues like inconsistent flavour and dry burning which are commonly seen in other disposable products. Thanks to the Constant Output Control and Patented Flavour-Lock Technology that FEELM Max adopts, we have achieved over 95% flavour consistency and a 30%-smoother vapour. We believe FEELM Max is taking the vaping experience to the next level as our harm reduction outperforms mainstream disposable products by 46%.”
In addition, the semi-translucent mouth-piece that FEELM Max recently introduced allows our users to check their e-liquid volume at all times.
“On top of our 14 R&D centres across the world, we recently opened China’s first PMTA-standard testing lab to help our brand partners improve their entry to the US market and complete their application process more easily – building on the success of our client Njoy, the first closed pod system to receive PMTA approval in the US.”
“Given the continued and increasing focus on ESG issues from our clients and their consumers, we are also working on a range of products that are made from eco-friendly materials. Our aim is to improve recyclability while developing biodegradable products which can decompose naturally. Driven by FEELM's latest ceramic coil technology, our new “Green Series” is leading the way. Batteries can be dismantled with ease for users to recycle, while other components can easily decompose. All of this is helping to bring down our carbon footprint while meeting the needs of our eco-conscious clients, and their customers. This is also proof of how we stick to our mission – atomization makes life better.”
In closing, Echo Liu welcomed the UKVIA’s first ever Economic Impact Assessment of the vaping industry, which FEELM hopes will prove how important the industry is to the UK economy and improving the public health of the nation by encouraging more smokers to switch.
ENDS
For more information or journalist queries, please contact us via feelm@smooretech.com.
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
About the UKVIA:
The UK Vaping Industry Association (UKVIA) is the #1 trade association for the vaping sector supporting, developing, and promoting the £1bn vaping industry, the UK’s largest growing consumer goods sector. Its vision is a world where the evidence-based, life-changing public health benefits of vaping products are fully understood so that their positive impact can be maximised.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005424/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Technology Innovation Institute Completes Asteroid-Landing Probe for Landmark Emirates Mission to the Asteroid Belt5.10.2026 09:42:00 CEST | Press release
In a first-of-its-kind mission, TII’s probe aboard the MBR Explorer will journey past six asteroids in the main belt before landing on 269 Justitia, making it only the seventh asteroid in history to be reached on its surface by a probeDesigned, built and tested in Abu Dhabi, TII’s probe is the mission’s only deployable payload, operating fully autonomously around and on JustitiaThought to have formed in the distant Kuiper Belt in the outer Solar System, 269 Justitia may preserve clues to how water and organic material were distributed during the formation of the planetsWatch the EMA hero film here The Technology Innovation Institute (TII) has revealed the UAE-built probe it has developed for the Emirates Mission to the Asteroid Belt (EMA). The probe will soon travel to Colorado, USA, for final integration with the MBR Explorer spacecraft ahead of its planned 2028 launch. In a historic first, TII’s probe will image two planets and seven asteroids — flying past six asteroids in the main
JEOL: Sales launch of HAXIS: The New Low-angle Ion Milling Scanning Electron Microscope5.10.2026 09:30:00 CEST | Press release
JEOL Ltd. (President & CEO Izumi Oi) announces the development of its new low‑angle ion‑milling scanning electron microscope, HAXIS, and will commence sales on October 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928207899/en/ HAXIS Low-angle Ion Milling Scanning Electron Microscope HAXIS Low-angle Ion Milling Scanning Electron Microscope Background of development As advanced semiconductor device structures continue to shrink and grow more complex, it has become difficult to contact and measure microscale circuits using nano-manipulators. In addition, contact caused by probing may affect the analysis target, necessitating new failure analysis methods. JEOL has conducted long-term research on the passive voltage contrast (PVC) detection technology and established a method for stable, highly reproducible PVC observation technology through the advancement of detectors and sample preparation techniques. HAXIS is JE
Slate Asset Management and OneIM Agree to Acquire Portfolio of Grocery-Anchored Essential Real Estate in the Greater Oslo Region Valued at Approximately €250 Million5.10.2026 08:30:00 CEST | Press release
Slate Asset Management ("Slate"), a global investor and manager focused on essential real estate and infrastructure assets, and One Investment Management (“OneIM”), a global alternative investment manager, today announced they have agreed to acquire a portfolio of eight grocery-anchored retail parks in Norway from Tellus Eiendom AS. The portfolio is located in the Greater Oslo region and is anchored by Norway's leading grocery operators and discount retailers. “We are pleased to be expanding our European Essential real estate platform with this significant acquisition,” said Brady Welch, Co-Founding Partner of Slate Asset Management. “These eight retail parks sit in dominant locations along major transport corridors around Oslo. The portfolio is anchored by Norway's strongest grocery operators and benefits from CPI-linked lease structures, designed to provide durable, inflation-protected cash flows. We look forward to applying our active management to unlock the portfolio’s full potent
Bial Showcases Parkinson’s Research at MDS 20265.10.2026 08:00:00 CEST | Press release
New data provide insights into the experiences and perceptions of people living with Parkinson’s and treatment outcomes Three posters and one oral presentation focus on the discontinued investigational compound BIA 28-6156 [INTENDED FOR MEDICAL AND TRADE MEDIA ONLY] Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, is presenting 16 scientific posters at the International Congress of Parkinson’s Disease and Movement Disorders (MDS 2026), taking place in Seoul, Korea, from 4 to 8 October. Reflecting Bial’s commitment to listening to and learning directly from people living with Parkinson’s, two presentations cover research initiatives focused on understanding their experiences, perspectives, and priorities. The first is the Patient Endpoint Preference Project (PEPP), an ongoing multinational observational study that seeks to identify and prioritise the symptoms and outcomes that matter most to people living with Parkinson’s. The second is th
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press release
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
